Israel Practice Co-Chair Bob Grossman led a multi-office team of Greenberg Traurig attorneys who represented longtime client OPKO HEALTH, INC. (NYSE:OPK) in the negotiation of a definitive merger agreement with Bio-Reference Laboratories, Inc. (NASDAQ:BRLI). OPKO is also traded as one of the largest companies on the Tel Aviv Stock Exchange. The $1.47 billion transaction, announced June 4, is expected to be completed during the second half of 2015.
OPKO is a multinational biopharmaceutical and diagnostics company. BRLI is considered one of the world’s largest and fastest-growing full-service diagnostic laboratories.
“We appreciate the opportunity to continue to work with OPKO and its Chairman and Chief Executive Officer Dr. Phillip Frost,” Grossman said. “Dr. Frost and his affiliated companies have been important longtime clients who have shown a deep commitment to Israel and an appreciation of the Israeli life science industry through the acquisition of PROLOR Biotech, along with other Israeli companies and technologies.”
In addition to representing Israeli companies, Greenberg Traurig’s Israel Practice provides assistance to Israeli and U.S. companies through introductions to strategic partners. Greenberg Traurig’s broad client base and network of offices and other resources are significant components of this process.
Read the firm’s press release for more information about the OPKO merger agreement.